Skip to main content

Advertisement

Table 1 Treatment of Acute Hereditary Angioedema - HAE - Attacks - 2010 XII 21

From: Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture

ANGIOEDEMA EVENT THERAPIES (AERx's)
TREAT AS EARLY AS POSSIBLE IN AN ATTACK
Plasma-derived C1 INH (pdC1INH) (intravenous) Berinert® CSL Behring - approved in many countries (including Europe and North America)
     ▪ 20 units/kg intravenously (FDA licensed dose)
  Cetor® Sanquin - approved in the Netherlands 1997
     ▪ 1000 units intravenously
  Cinryze® ViroPharma - under review for therapy
Recombinant C1INH (rhC1INH) (intravenous) conestat alfa, Rhucin® non-European and Ruconest® in Europe; Pharming
     ▪ 50 units/kg intravenously
  approved for use by the European Medicines Agency (EMA) for use in the European Union 2010
  under review in North America
Bradykinin B2 receptor antagonist (subcutaneous) Icatibant - 30 mg (subcutaneous) (Firazyr® (Jerini/Shire)
  approved for use by the European Medicines Agency (EMA) for use in the European Union 2008
  not yet approved in North America
Kallikrein receptor antagonist (subcutaneous) Ecallantide, Dyax, DX-88, Kalbitor®
  30 mg subcutaneously
  approved USA 2009 - not yet available in Canada
  1. *Modified from: www.haecanada.com and 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema - Bowen et al. Allergy, Asthma & Clinical Immunology 2010, 6 :24 - http://www.aacijournal.com/content/6/1/24)